DESTINY: achieving TFR by de-escalating therapy in CML

DESTINY: achieving TFR by de-escalating therapy in CML

VJHemOnc

1 year
97 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Richard Clark, MA, MD, MRCP, FRCPath, of the Royal Liverpool University Hospital, Liverpool, UK, presented the final results of the DESTINY trial (NCT01804985) at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. This trial investigated the effect of de-escalating imatinib, nilotinib or dasatinib therapies for chronic myeloid leukemia (CML) patients who had achieved major molecular response (MMR), but not necessarily MR4. Though responses from non-MR4 patients were not as good as those who had achieved this status, Prof. Clark emphasizes that these data provide a good rationale for de-escalating treatment across MMR patients in order to achieve treatment-free remission (TFR).
Up Next Autoplay
Treating CML & Myelofibrosis Patients
Treating CML & Myelofibrosis Patients
Category: Chronic Myelogenous Leukemia
317 Views
imedex 10 months
Resistance/intolerance to second generation TKIs in CML: what to do next?
Resistance/intolerance to second generation TKIs in CML: what to do next?
Category: Chronic Myelogenous Leukemia
153 Views
VJHemOnc 1 year
Update on ENESTop: TFR in CML after discontinuing nilotinib
Update on ENESTop: TFR in CML after discontinuing nilotinib
Category: Chronic Myelogenous Leukemia
126 Views
VJHemOnc 1 year
Benefits of second generation TKIs for CML in the frontline
Benefits of second generation TKIs for CML in the frontline
Category: Chronic Myelogenous Leukemia
92 Views
VJHemOnc 1 year
Personalized therapy in leukemia: a case study
Personalized therapy in leukemia: a case study
Category: Chronic Myelogenous Leukemia
236 Views
VJHemOnc 1 year
New drugs for CML: are more to come?
New drugs for CML: are more to come?
Category: Chronic Myelogenous Leukemia
63 Views
VJHemOnc 1 year
Bosutinib: a new, safer TKI for frontline CML
Bosutinib: a new, safer TKI for frontline CML
Category: Chronic Myelogenous Leukemia
92 Views
VJHemOnc 1 year
Asciminib has the potential to succeed where other TKIs have failed in CML
Asciminib has the potential to succeed where other TKIs have failed in CML
Category: Chronic Myelogenous Leukemia
210 Views
VJHemOnc 1 year
Novel agents or imatinib for CML in the frontline setting?
Novel agents or imatinib for CML in the frontline setting?
Category: Chronic Myelogenous Leukemia
74 Views
VJHemOnc 1 year